IOVAIovance Biotherapeutics, Inc.
$14.08+529% 1Y
$14.08
$1.8152 weeks$14.87
Is the business good?
Mixed
1 to watch, 1 neutral, 2 without dataThe checks split: nothing decisive, though 3 of 9 health tests passed.
Fundamental health (F-score)3 / 9SEC EDGAR · Dec 31, 2025
Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is IOVA?
Iovance Biotherapeutics, Inc. keeps −93% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
−93%
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- R&D as % of revenue
- 82%
R&D as % of revenue
- Gross margin
- 48%
Gross margin
| Year | Operating margin |
|---|---|
| FY2023 | −38735% |
| FY2024 | −241% |
| FY2025 | −153% |
Details›
- Gross margin12 months to Q2 2026
- 48%
- Operating margin12 months to Q2 2026
- −93%
- Net margin12 months to Q2 2026
- −89%
- Free cash flow margin
- −91%
- R&D as % of revenue
- 82%
- Revenue, trailing twelve months
- $325M
- Free cash flow, trailing twelve months
- −$296M
- Net income, trailing twelve months
- −$290M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks